Repurposing the Insecticide Flufenerim, the Only Anti- Cryptococcus Compound Identified in the MMV Global Health Priority Box, as a Candidate for the Environmental Control of the Cryptococcosis Agents
6 affiliations
- 1Fundação Oswaldo Cruz , , , ,
- 2Universidade Federal de São Paulo , , ,
- 3Universidade Federal do Rio de Janeiro , , , ,
- 4Universidade Federal Fluminense , , , ,
- 5Universidade de São Paulo , , , ,
- 6Fundação de Amparo á Pesquisa do Estado do Rio de Janeiro (FAPERJ) , , , ,
Abstract
Cryptococcus neoformans and Cryptococcus gattii are environmental fungi that cause cryptococcosis, a severe, life-threatening infection, particularly in immunocompromised individuals. Current treatments are limited by toxicity, restricted availability, and the emergence of resistance, highlighting the need for novel antifungal agents. Here, 240 compounds from the Medicines for Malaria Venture (MMV) Global Health Priority Box were screened for activity against these two species. Flufenerim, originally developed as an insecticide, was the only compound that exhibited inhibitory activity at 1 μM (0.364 μg/mL). Minimum inhibitory concentrations ranged from 0.03 μg/mL to >8 μg/mL across 15 isolates, and the compound exhibited a predominantly fungistatic profile, except for one C. gattii strain. At subinhibitory concentrations, flufenerim significantly reduced capsule thickness in both species, melanization in C. neoformans, and urease production in C. gattii, without affecting phospholipase activity. In silico ADMET predictions indicated predicted toxicological risks requiring further evaluation. Cytotoxicity assays further demonstrated that the compound did not exhibit significant toxicity in murine and human macrophages, nor in human brain endothelial cells (HBECs). Exposure of Galleria mellonella larvae to flufenerim produced sublethal physiological effects without mortality. Due to the unfavorable ADMET profile, we evaluated whether this compound could be used for environmental control of fungal reservoirs. Tree-hollow samples spiked with C. neoformans and treated with flufenerim yielded fewer yeast colonies than untreated controls when plated on Staib’s agar. These findings identify flufenerim as a new anti-Cryptococcus compound and provide preliminary evidence supporting its potential for reducing C. neoformans recovery from environmental substrates. However, the ecological complexity of Cryptococcus reservoirs and the potential effects on nontarget microorganisms require extensive investigation before any environmental application can be considered.
Related
- Laryngeal cryptococcosis with clinical failure to fluconazole in a patient with common variable immunodeficiency: A treatment dilemma
- Pulmonary Cryptococcosis Mimicking Lung Metastasis in a Patient with Pancreatic Cancer: A Case Report and Review of the Literature
- Macropinocytosis mediates neurotropism of Cryptococcus neoformans in a human organoid model of the blood-brain barrier
- Protective association between recent insecticide-treated bed net use and falciparum malaria in three provinces of the Democratic Republic of the Congo
- High-throughput phenotypic profiling of insecticide responses in mosquito larvae
BibTeX
@article{godoy2026repurposing,
title = {{Repurposing the Insecticide Flufenerim, the Only Anti- Cryptococcus Compound Identified in the MMV Global Health Priority Box, as a Candidate for the Environmental Control of the Cryptococcosis Agents}},
author = {Juliana Godoy and Iara Bastos de Andrade and Edinaldo Castro de Oliveira and Igor Avellar-Moura and Kamilla Xavier Gomes and Felipe Carvalho da Costa and Marcelo Kurgonas de Oliveira and Carlos Pelleschi Taborda and Allan Jefferson Guimarães and Rosely Maria Zancopé-Oliveira and Marcos Abreu Almeida and Susana Frases and Rodrigo Almeida-Paes},
journal = {ACS Omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.6c04207},
url = {https://pubs.acs.org/acsodf/article/11/41/62717/5444964/Repurposing-the-Insecticide-Flufenerim-the-Only},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Repurposing the Insecticide Flufenerim, the Only Anti- Cryptococcus Compound Identified in the MMV Global Health Priority Box, as a Candidate for the Environmental Control of the Cryptococcosis Agents
AU - Juliana Godoy
AU - Iara Bastos de Andrade
AU - Edinaldo Castro de Oliveira
AU - Igor Avellar-Moura
AU - Kamilla Xavier Gomes
AU - Felipe Carvalho da Costa
AU - Marcelo Kurgonas de Oliveira
AU - Carlos Pelleschi Taborda
AU - Allan Jefferson Guimarães
AU - Rosely Maria Zancopé-Oliveira
AU - Marcos Abreu Almeida
AU - Susana Frases
AU - Rodrigo Almeida-Paes
PY - 2026
DA - 2026/10/06
JO - ACS Omega
DO - 10.1021/acsomega.6c04207
UR - https://pubs.acs.org/acsodf/article/11/41/62717/5444964/Repurposing-the-Insecticide-Flufenerim-the-Only
AB - Cryptococcus neoformans and Cryptococcus gattii are environmental fungi that cause cryptococcosis, a severe, life-threatening infection, particularly in immunocompromised individuals. Current treatments are limited by toxicity, restricted availability, and the emergence of resistance, highlighting the need for novel antifungal agents. Here, 240 compounds from the Medicines for Malaria Venture (MMV) Global Health Priority Box were screened for activity against these two species. Flufenerim, originally developed as an insecticide, was the only compound that exhibited inhibitory activity at 1 μM (0.364 μg/mL). Minimum inhibitory concentrations ranged from 0.03 μg/mL to >8 μg/mL across 15 isolates, and the compound exhibited a predominantly fungistatic profile, except for one C. gattii strain. At subinhibitory concentrations, flufenerim significantly reduced capsule thickness in both species, melanization in C. neoformans, and urease production in C. gattii, without affecting phospholipase activity. In silico ADMET predictions indicated predicted toxicological risks requiring further evaluation. Cytotoxicity assays further demonstrated that the compound did not exhibit significant toxicity in murine and human macrophages, nor in human brain endothelial cells (HBECs). Exposure of Galleria mellonella larvae to flufenerim produced sublethal physiological effects without mortality. Due to the unfavorable ADMET profile, we evaluated whether this compound could be used for environmental control of fungal reservoirs. Tree-hollow samples spiked with C. neoformans and treated with flufenerim yielded fewer yeast colonies than untreated controls when plated on Staib’s agar. These findings identify flufenerim as a new anti-Cryptococcus compound and provide preliminary evidence supporting its potential for reducing C. neoformans recovery from environmental substrates. However, the ecological complexity of Cryptococcus reservoirs and the potential effects on nontarget microorganisms require extensive investigation before any environmental application can be considered.
SN - 2470-1343
ER -